Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment

Eva V. Varga, Henry I. Yamamura, Marc K. Rubenzik, Dagmar Stropova, Edita Navratilova, William R Roeske

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Opioid receptor agonists mediate their analgesic effects by interacting with Gi/o protein-coupled opioid receptors. Acute treatment with opioid agonists is thought to mediate analgesia by hyperpolarization of presynatic neurons, leading to the inhibition of excitatory (pain) neurotransmitters release. After chronic treatment however, the opioid receptors gradually become less responsive to agonists, and increased drug doses become necessary to maintain the therapeutic effect (tolerance). Analgesic tolerance is the result of two, partially overlapping processes: a gradual loss of inhibitory opioid function is accompanied by an increase in excitatory signaling. Recent data indicate that chronic opioid agonist treatment simultaneously desensitizes the inhibitory-, and augments the stimulatory effects of the opioids. In the present paper we review the molecular mechanisms that may have a role in the augmentation of the excitatory signaling upon chronic opioid agonist treatment. We also briefly review our recent experimental data on the molecular mechanism of chronic opioid agonist-mediated functional sensitization of forskolin-stimulated cAMP formation, in a recombinant Chinese hamster ovary cell line stably expressing the human δ-opioid receptor (hDOR/CHO). To interpret the experimental data, we propose that chronic hDOR activaton leads to activation of multiple redundant signaling pathways that converge to activate the protein kinase, Raf-1. Raf-1 in turn phosphorylates and sensitizes the native adenylyl cyclase VI isoenzyme in hDOR/CHO cells, causing a rebound increase in forskolin-stimulated cAMP formation upon agonist withdrawal.

Original languageEnglish (US)
Pages (from-to)299-311
Number of pages13
JournalLife Sciences
Volume74
Issue number2-3
DOIs
StatePublished - Dec 5 2003

Fingerprint

Opioid Analgesics
Opioid Receptors
Colforsin
Analgesics
Therapeutics
Proto-Oncogene Proteins c-raf
CHO Cells
Therapeutic Uses
Cricetulus
Analgesia
Protein Kinases
Isoenzymes
Neurons
Neurotransmitter Agents
Ovary
Chemical activation
Cells
Pain
Cell Line
Pharmaceutical Preparations

Keywords

  • Adenylyl cyclase superactivation
  • Chronic opioid treatment
  • Excitatory signal transduction
  • Opioid-mediated pain

ASJC Scopus subject areas

  • Pharmacology

Cite this

Varga, E. V., Yamamura, H. I., Rubenzik, M. K., Stropova, D., Navratilova, E., & Roeske, W. R. (2003). Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment. Life Sciences, 74(2-3), 299-311. https://doi.org/10.1016/j.lfs.2003.09.017

Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment. / Varga, Eva V.; Yamamura, Henry I.; Rubenzik, Marc K.; Stropova, Dagmar; Navratilova, Edita; Roeske, William R.

In: Life Sciences, Vol. 74, No. 2-3, 05.12.2003, p. 299-311.

Research output: Contribution to journalArticle

Varga, EV, Yamamura, HI, Rubenzik, MK, Stropova, D, Navratilova, E & Roeske, WR 2003, 'Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment', Life Sciences, vol. 74, no. 2-3, pp. 299-311. https://doi.org/10.1016/j.lfs.2003.09.017
Varga, Eva V. ; Yamamura, Henry I. ; Rubenzik, Marc K. ; Stropova, Dagmar ; Navratilova, Edita ; Roeske, William R. / Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment. In: Life Sciences. 2003 ; Vol. 74, No. 2-3. pp. 299-311.
@article{caccaeded097411abddcbe3e6d5cb788,
title = "Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment",
abstract = "Opioid receptor agonists mediate their analgesic effects by interacting with Gi/o protein-coupled opioid receptors. Acute treatment with opioid agonists is thought to mediate analgesia by hyperpolarization of presynatic neurons, leading to the inhibition of excitatory (pain) neurotransmitters release. After chronic treatment however, the opioid receptors gradually become less responsive to agonists, and increased drug doses become necessary to maintain the therapeutic effect (tolerance). Analgesic tolerance is the result of two, partially overlapping processes: a gradual loss of inhibitory opioid function is accompanied by an increase in excitatory signaling. Recent data indicate that chronic opioid agonist treatment simultaneously desensitizes the inhibitory-, and augments the stimulatory effects of the opioids. In the present paper we review the molecular mechanisms that may have a role in the augmentation of the excitatory signaling upon chronic opioid agonist treatment. We also briefly review our recent experimental data on the molecular mechanism of chronic opioid agonist-mediated functional sensitization of forskolin-stimulated cAMP formation, in a recombinant Chinese hamster ovary cell line stably expressing the human δ-opioid receptor (hDOR/CHO). To interpret the experimental data, we propose that chronic hDOR activaton leads to activation of multiple redundant signaling pathways that converge to activate the protein kinase, Raf-1. Raf-1 in turn phosphorylates and sensitizes the native adenylyl cyclase VI isoenzyme in hDOR/CHO cells, causing a rebound increase in forskolin-stimulated cAMP formation upon agonist withdrawal.",
keywords = "Adenylyl cyclase superactivation, Chronic opioid treatment, Excitatory signal transduction, Opioid-mediated pain",
author = "Varga, {Eva V.} and Yamamura, {Henry I.} and Rubenzik, {Marc K.} and Dagmar Stropova and Edita Navratilova and Roeske, {William R}",
year = "2003",
month = "12",
day = "5",
doi = "10.1016/j.lfs.2003.09.017",
language = "English (US)",
volume = "74",
pages = "299--311",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "2-3",

}

TY - JOUR

T1 - Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment

AU - Varga, Eva V.

AU - Yamamura, Henry I.

AU - Rubenzik, Marc K.

AU - Stropova, Dagmar

AU - Navratilova, Edita

AU - Roeske, William R

PY - 2003/12/5

Y1 - 2003/12/5

N2 - Opioid receptor agonists mediate their analgesic effects by interacting with Gi/o protein-coupled opioid receptors. Acute treatment with opioid agonists is thought to mediate analgesia by hyperpolarization of presynatic neurons, leading to the inhibition of excitatory (pain) neurotransmitters release. After chronic treatment however, the opioid receptors gradually become less responsive to agonists, and increased drug doses become necessary to maintain the therapeutic effect (tolerance). Analgesic tolerance is the result of two, partially overlapping processes: a gradual loss of inhibitory opioid function is accompanied by an increase in excitatory signaling. Recent data indicate that chronic opioid agonist treatment simultaneously desensitizes the inhibitory-, and augments the stimulatory effects of the opioids. In the present paper we review the molecular mechanisms that may have a role in the augmentation of the excitatory signaling upon chronic opioid agonist treatment. We also briefly review our recent experimental data on the molecular mechanism of chronic opioid agonist-mediated functional sensitization of forskolin-stimulated cAMP formation, in a recombinant Chinese hamster ovary cell line stably expressing the human δ-opioid receptor (hDOR/CHO). To interpret the experimental data, we propose that chronic hDOR activaton leads to activation of multiple redundant signaling pathways that converge to activate the protein kinase, Raf-1. Raf-1 in turn phosphorylates and sensitizes the native adenylyl cyclase VI isoenzyme in hDOR/CHO cells, causing a rebound increase in forskolin-stimulated cAMP formation upon agonist withdrawal.

AB - Opioid receptor agonists mediate their analgesic effects by interacting with Gi/o protein-coupled opioid receptors. Acute treatment with opioid agonists is thought to mediate analgesia by hyperpolarization of presynatic neurons, leading to the inhibition of excitatory (pain) neurotransmitters release. After chronic treatment however, the opioid receptors gradually become less responsive to agonists, and increased drug doses become necessary to maintain the therapeutic effect (tolerance). Analgesic tolerance is the result of two, partially overlapping processes: a gradual loss of inhibitory opioid function is accompanied by an increase in excitatory signaling. Recent data indicate that chronic opioid agonist treatment simultaneously desensitizes the inhibitory-, and augments the stimulatory effects of the opioids. In the present paper we review the molecular mechanisms that may have a role in the augmentation of the excitatory signaling upon chronic opioid agonist treatment. We also briefly review our recent experimental data on the molecular mechanism of chronic opioid agonist-mediated functional sensitization of forskolin-stimulated cAMP formation, in a recombinant Chinese hamster ovary cell line stably expressing the human δ-opioid receptor (hDOR/CHO). To interpret the experimental data, we propose that chronic hDOR activaton leads to activation of multiple redundant signaling pathways that converge to activate the protein kinase, Raf-1. Raf-1 in turn phosphorylates and sensitizes the native adenylyl cyclase VI isoenzyme in hDOR/CHO cells, causing a rebound increase in forskolin-stimulated cAMP formation upon agonist withdrawal.

KW - Adenylyl cyclase superactivation

KW - Chronic opioid treatment

KW - Excitatory signal transduction

KW - Opioid-mediated pain

UR - http://www.scopus.com/inward/record.url?scp=0242289614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242289614&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2003.09.017

DO - 10.1016/j.lfs.2003.09.017

M3 - Article

C2 - 14607258

AN - SCOPUS:0242289614

VL - 74

SP - 299

EP - 311

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 2-3

ER -